3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
129
Carcinoma, Renal Cell
36
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Neoplasms
27
Cholangiocarcinoma
23
Endometrial Neoplasms
19
Liver Neoplasms
16
Melanoma
15
Thyroid Neoplasms
13
Stomach Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Biliary Tract Neoplasms
12
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Ovarian Neoplasms
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Small Cell Lung Carcinoma
5
Neuroendocrine Tumors
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Solid Tumors
3
Interventions
Gemcitabine
157
Cisplatin
116
pembrolizumab
80
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Cystectomy
40
Docetaxel
38
atezolizumab
33
Magnetic Resonance Spectroscopy
31
durvalumab
30
Radiotherapy
29
BCG Vaccine
26
avelumab
24
Specimen Handling
24
Doxorubicin
23
enfortumab vedotin
22
Fluorouracil
20
Cystoscopy
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Filgrastim
14
Transurethral Resection of Bladder
13
Sunitinib
13
Ipilimumab
13
vinflunine
12
5-aminolevulinic acid hexyl ester
12
tremelimumab
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Neoplasms
×
lenvatinib
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled